Medications development for the treatment of nicotine dependence in individuals with schizophrenia

Journal of Dual Diagnosis

Volumn 3, Issue 3-4, 2007, Pages 113-150

  Montoya, Ivan D ^a   Vocci, Frank ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Comorbidity; Nicotine; Pharmacotherapy; Schizophrenia; Smoking; Treatment

Indexed keywords

2,4 DIMETHOXYBENZYLDINE ANABASEINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; HALOPERIDOL; MECAMYLAMINE; MONOAMINE OXIDASE INHIBITOR; NALTREXONE; NEUROLEPTIC AGENT; NICOTINE; NICOTINE VACCINE; NICOTINIC RECEPTOR BLOCKING AGENT; OLANZAPINE; OPIATE AGONIST; OPIATE ANTAGONIST; PAROXETINE; PERPHENAZINE; PLACEBO; RIMONABANT; RISPERIDONE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TROPISETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE;

ATTENTION; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; COMORBIDITY; DRUG APPROVAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EVOKED AUDITORY RESPONSE; FOLLOW UP; GROUP THERAPY; HUMAN; MEMORY DISORDER; MONOTHERAPY; NEUROBIOLOGY; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PARKINSONISM; PATHOPHYSIOLOGY; PHARMACOGENETICS; PREVALENCE; PUBLIC HEALTH SERVICE; REPEATED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SMOKING CESSATION; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; WORKING MEMORY;

EID: 36448977658     PISSN: 15504263     EISSN: 15504271     Source Type: Journal    
DOI: 10.1300/J374v03n03_09     Document Type: Review

References (146)

1. Addington, J., El Guebaly, N., Campbell, W., Hodgins, D. C., & Addington, D. (1998). Smoking cessation treatment for patients with schizophrenia. Am.J.Psychiatry, 155, 974-976.
2. Addy, N. & Levin, E. D. (2002). Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. Neuropsychopharmacology, 27, 534-541.
3. Andreassen, O. A. & Steen, V. M. (2006). [Pharmacogenetics and tailored drug treatment in schizophrenia]. Tidsskr.Nor Laegeforen., 126, 2400-2402.
4. Apud, J. A., Egan, M. F., & Wyatt, R. J. (2000). Effects of smoking during antipsychotic withdrawal in patients with chronic schizophrenia. Schizophr.Res., 46, 119-127.
5. Arango, C., Buchanan, R. W., Kirkpatrick, B., & Carpenter, W. T. (2004). The deficit syndrome in schizophrenia: Implications for the treatment of negative symptoms. Eur.Psychiatry, 19, 21-26.
6. Arguello, P. A. & Jentsch, J. D. (2004). Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat. Psychopharmacology (Berl), 177, 141-150.
7. Astrup, A. & Toubro, S. (2004). Topiramate: A new potential pharmacological treatment for obesity. Obes.Res., 12 Suppl, 167S-173S.
8. Barnes, M., Lawford, B. R., Burton, S. C., Heslop, K. R., Noble, E. P., Hausdorf, K. et al. (2006). Smoking and schizophrenia: Is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? Aust. N.Z.J.Psychiatry, 40, 575-580.
9. Berlin, I., Said, S., Spreux-Varoquaux, O., Olivares, R., Launay, J. M., & Puech, A. J. (1995). Monoamine oxidase A and B activities in heavy smokers. Biol.Psychiatry, 38, 756-761.
10. Berrettini, W. H. & Lerman, C. E. (2005). Pharmacotherapy and pharmacogenetics of nicotine dependence. Am.J.Psychiatry, 162, 1441-1451.
11. Biberman, R., Neumann, R., Katzir, I., & Gerber, Y. (2003). A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction, 98, 1403-1407.
12. Bombin, I., Arango, C., & Buchanan, R. W. (2005). Significance and meaning of neurological signs in schizophrenia: Two decades later. Schizophr.Bull., 31, 962-977.
13. Breese, C. R., Lee, M. J., Adams, C. E., Sullivan, B., Logel, J., Gillen, K. M. et al. (2000). Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology, 23, 351-364.
14. Breese, C. R., Marks, M. J., Logel, J., Adams, C. E., Sullivan, B., Collins, A. C. et al. (1997). Effect of smoking history on [3H]nicotine binding in human postmortem brain. J.Pharmacol.Exp.Ther., 282, 7-13.
15. Brody, A. L. (2006). Functional brain imaging of tobacco use and dependence. J.Psychiatr Res., 40, 404-418.
16. Brody, A. L., Mandelkern, M. A., Olmstead, R. E., Scheibal, D., Hahn, E., Shiraga, S. et al. (2006). Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch.Gen.Psychiatry, 63, 808-816.
17. Bucci, L. (1987). The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology (Berl), 91, 104-108.
18. Carpenter, W. T. (2006). The schizophrenia paradigm: A hundred-year challenge. J.Nerv.Ment.Dis., 194, 639-643.
19. Caskey, N. H., Jarvik, M. E., & Wirshing, W. C. (1999). The effects of dopaminergic D2 stimulation and blockade on smoking behavior. Exp.Clin.Psychopharmacol., 7, 72-78.
20. Chaudhri, N., Caggiula, A. R., Donny, E. C., Palmatier, M. I., Liu, X., & Sved, A. F. (2006). Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. Psychopharmacology (Berl), 184, 353-366.
21. Chou, K. R., Chen, R., Lee, J. F., Ku, C. H., & Lu, R. B. (2004). The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int.J.Nurs.Stud., 41, 321-330.
22. Cinciripini, P. M., Tsoh, J. Y., Wetter, D. W., Lam, C., de Moor, C., Cinciripini, L. et al. (2005). Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation. Exp.Clin. Psychopharmacol., 13, 282-292.
23. Combs, D. R. & Advokat, C. (2000). Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia. Schizophr.Res., 46, 129-137.
24. Corrigall, W. A., Franklin, K. B., Coen, K. M., & Clarke, P. B. (1992). The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl), 107, 285-289.
25. Covey, L. S., Glassman, A. H., & Stetner, F. (1999). Naltrexone effects on short-term and long-term smoking cessation. J.Addict.Dis., 18, 31-40.
26. Curkendall, S. M., Mo, J., Glasser, D. B., Rose, S. M., & Jones, J. K. (2004). Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J.Clin.Psychiatry, 65, 715-720.
27. Dalack, G. W., Becks, L., Hill, E., Pomerleau, O. F., & Meador-Woodruff, J. H. (1999). Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology, 21, 195-202.
28. Dalack, G. W. & Meador-Woodruff, J. H. (1996). Smoking, smoking withdrawal and schizophrenia: Case reports and a review of the literature. Schizophr.Res., 22, 133-141.
29. Dalack, G. W. & Meador-Woodruff, J. H. (1999). Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia. Nicotine.Tob.Res., 1, 53-57.
30. Dalack, G. W., Ritter, L. M., & Meador-Woodruff, J. H. (2000). Nicotine replacement and smoking suppression in schizophrenia. Biol Psychiatry, 47, S48.
31. David, S., Lancaster, T., Stead, L. F., & Evins, A. E. (2006). Opioid antagonists for smoking cessation. Cochrane.Database.Syst.Rev., CD003086.
32. Davidson, M., Caspi, A., & Noy, S. (2005). The treatment of schizophrenia: From premorbid manifestations to the first episode of psychosis. Dialogues. Clin. Neurosci., 7, 7-16.
33. Dawe, S., Gerada, C., Russell, M. A., & Gray, J. A. (1995). Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology (Berl), 117, 110-115.
34. de Leon, J. & Diaz, F. J. (2005). A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr.Res., 76, 135-157.
35. Depatie, L., O'Driscoll, G. A., Holahan, A. L., Atkinson, V., Thavundayil, J. X., Kin, N. N. et al. (2002). Nicotine and behavioral markers of risk for schizophrenia: A double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology, 27, 1056-1070.
36. Elrod, K., Buccafusco, J. J., & Jackson, W. J. (1988). Nicotine enhances delayed matching-to-sample performance by primates. Life Sci., 43, 277-287.
37. Ereshefsky, L., Jann, M. W., Saklad, S. R., Davis, C. M., Richards, A. L., & Burch, N. R. (1985). Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol.Psychiatry, 20, 329-332.
38. Erhart, S. M., Marder, S. R., & Carpenter, W. T. (2006). Treatment of schizophrenia negative symptoms: Future prospects. Schizophr.Bull., 32, 234-237.
39. Evins, A. E., Cather, C., Deckersbach, T., Freudenreich, O., Culhane, M. A., Olm-Shipman, C. M. et al. (2005a). A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J.Clin. Psychopharmacol., 25, 218-225.
40. Evins, A. E., Cather, C., Rigotti, N. A., Freudenreich, O., Henderson, D. C., Olm-Shipman, C. M. et al. (2004). Two-year follow-up of a smoking cessation trial in patients with schizophrenia: Increased rates of smoking cessation and reduction. J.Clin. Psychiatry, 65, 307-311.
41. Evins, A. E., Deckersbach, T., Cather, C., Freudenreich, O., Culhane, M. A., Henderson, D. C. et al. (2005b). Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J.Clin.Psychiatry, 66, 1184-1190.
42. Evins, A. E., Mays, V. K., Rigotti, N. A., Tisdale, T., Cather, C., & Goff, D. C. (2001). A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine.Tob.Res., 3, 397-403.
43. Evins, A. E. & Tisdale, T. (1999). Bupropion and smoking cessation. Am.J.Psychiatry, 156, 798-799.
44. Fagerstrom, K. & Balfour, D. J. (2006). Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert.Opin.Investig.Drugs, 15, 107-116.
45. Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., & Moller, H. J. (2005). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: Acute treatment of schizophrenia. World J.Biol Psychiatry, 6, 132-191.
46. Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., & Moller, H. J. (2006). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 2: Long-term treatment of schizophrenia. World J.Biol Psychiatry, 7, 5-40.
47. Foulds, J., Steinberg, M. B., Williams, J. M., & Ziedonis, D. M. (2006). Developments in pharmacotherapy for tobacco dependence: Past, present and future. Drug Alcohol Rev., 25, 59-71.
48. Fowler, J. S., Volkow, N. D., Wang, G. J., Pappas, N., Logan, J., MacGregor, R. et al. (1996). Inhibition of monoamine oxidase B in the brains of smokers. Nature, 379, 733-736.
49. Frishman, W. H., Mitta, W., Kupersmith, A., & Ky, T. (2006). Nicotine and non-nicotine smoking cessation pharmacotherapies. Cardiol.Rev., 14, 57-73.
50. George, T. P., Sernyak, M. J., Ziedonis, D. M., & Woods, S. W. (1995). Effects of clozapine on smoking in chronic schizophrenic outpatients. J.Clin.Psychiatry, 56, 344-346.
51. George, T. P., Termine, A., Sacco, K. A., Allen, T. M., Reutenauer, E., Vessicchio, J. C. et al. (2006). A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: Involvement of nicotinic receptor mechanisms. Schizophr.Res., 87, 307-315.
52. George, T. P., Vessicchio, J. C., Termine, A., Bregartner, T. A., Feingold, A., Rounsaville, B. J. et al. (2002a). A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol.Psychiatry, 52, 53-61.
53. George, T. P., Vessicchio, J. C., Termine, A., Jatlow, P. I., Kosten, T. R., & O'Malley, S. S. (2003). A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol.Psychiatry, 53, 136-143.
54. George, T. P., Vessicchio, J. C., Termine, A., Sahady, D. M., Head, C. A., Pepper, W. T. et al. (2002b). Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology, 26, 75-85.
55. George, T. P., Ziedonis, D. M., Feingold, A., Pepper, W. T., Satterburg, C. A., Winkel, J. et al. (2000). Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am.J.Psychiatry, 157, 1835-1842.
56. Gobbi, G., Gaudreau, P. O., & Leblanc, N. (2006). Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. J.Clin.Psychopharmacol., 26, 467-473.
57. Gobbi, G., Slater, S., Boucher, N., Debonnel, G., & Blier, P. (2003). Neurochemical and psychotropic effects of bupropion in healthy male subjects. J. Clin. Psychopharmacol., 23, 233-239.
58. Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B. et al. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA, 296, 47-55.
59. Gupta, S., Jain, S., Brahmachari, S. K., & Kukreti, R. (2006). Pharmacogenomics: A path to predictive medicine for schizophrenia. Pharmacogenomics., 7, 31-47.
60. Haring, C., Meise, U., Humpel, C., Saria, A., Fleischhacker, W. W., & Hinterhuber, H. (1989). Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology (Berl), 99 Suppl, S38-S40.
61. Harris, J. G., Kongs, S., Allensworth, D., Martin, L., Tregellas, J., Sullivan, B. et al. (2004). Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology, 29, 1378-1385.
62. Hartman, N., Leong, G. B., Glynn, S. M., Wilkins, J. N., & Jarvik, M. E. (1991). Transdermal nicotine and smoking behavior in psychiatric patients. Am.J.Psychiatry, 148, 374-375.
63. Hasegawa, M., Gutierrez-Esteinou, R., Way, L., & Meltzer, H. Y. (1993). Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking. J.Clin.Psychopharmacol., 13, 383-390.
64. Hatsukami, D. K., Rennard, S., Jorenby, D., Fiore, M., Koopmeiners, J., de Vos, A. et al. (2005). Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin.Pharmacol.Ther., 78, 456-467.
65. Heidbreder, C. A., Gardner, E. L., Xi, Z. X., Thanos, P. K., Mugnaini, M., Hagan, J. J. et al. (2005). The role of central dopamine D3 receptors in drug addiction: A review of pharmacological evidence. Brain Res.Brain Res.Rev., 49, 77-105.
66. Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005). Schizophrenia and increased risks of cardiovascular disease. Am.Heart J., 150, 1115-1121.
67. Hertel, P., Nomikos, G. G., Iurlo, M., & Svensson, T. H. (1996). Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berl), 124, 74-86.
68. Hitsman, B., Pingitore, R., Spring, B., Mahableshwarkar, A., Mizes, J. S., Segraves, K. A. et al. (1999). Antidepressant pharmacotherapy helps some cigarette smokers more than others. J.Consult Clin.Psychol., 67, 547-554.
69. Hogg, R. C. & Bertrand, D. (2004). Nicotinic acetylcholine receptors as drug targets. Curr.Drug Targets.CNS.Neurol.Disord., 3, 123-130.
70. Hogg, R. C. & Bertrand, D. (2006). Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors. Biochem.Pharmacol..
71. Hurt, R. D., Sachs, D. P., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C. et al. (1997). A comparison of sustained-release bupropion and placebo for smoking cessation. N.Engl.J.Med., 337, 1195-1202.
72. Hutchison, K. E., Rutter, M. C., Niaura, R., Swift, R. M., Pickworth, W. B., & Sobik, L. (2004). Olanzapine attenuates cue-elicited craving for tobacco. Psychopharmacology (Berl), 175, 407-413.
73. Jann, M. W., Saklad, S. R., Ereshefsky, L., Richards, A. L., Harrington, C. A., & Davis, C. M. (1986). Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Berl), 90, 468-470.
74. Johnson, B. A., Ait-Daoud, N., Akhtar, F. Z., & Javors, M. A. (2005). Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: A randomized controlled trial. Arch.Intern.Med., 165, 1600-1605.
75. Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R. et al. (1999). A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N.Engl.J.Med., 340, 685-691.
76. Kirkpatrick, B., Fenton, W. S., Carpenter, W. T., Jr., & Marder, S. R. (2006). The NIMH-MATRICS consensus statement on negative symptoms. Schizophr.Bull., 32, 214-219.
77. Kirkpatrick, B., Messias, E. M., & Tek, C. (2003). Substance abuse and the heterogeneity of schizophrenia a population-based study. Schizophr.Res., 62, 293-294.
78. Koike, K., Hashimoto, K., Takai, N., Shimizu, E., Komatsu, N., Watanabe, H. et al. (2005). Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr.Res., 76, 67-72.
79. Kumari, V. & Postma, P. (2005). Nicotine use in schizophrenia: The self medication hypotheses. Neurosci.Biobehav.Rev., 29, 1021-1034.
80. Lancaster, T. & Stead, L. F. (2000). Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane.Database.Syst.Rev., CD001009.
81. Laviolette, S. R. & Grace, A. A. (2006a). Cannabinoids Potentiate Emotional Learning Plasticity in Neurons of the Medial Prefrontal Cortex through Basolateral Amygdala Inputs. J.Neurosci., 26, 6458-6468.
82. Laviolette, S. R. & Grace, A. A. (2006b). The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: Implications for schizophrenia and addiction. Cell Mol.Life Sci., 63, 1597-1613.
83. Laviolette, S. R. & van der Kooy, D. (2004). The neurobiology of nicotine addiction: Bridging the gap from molecules to behaviour. Nat.Rev.Neurosci., 5, 55-65.
84. Le Foll, B., Goldberg, S. R., & Sokoloff, P. (2007). Dopamine D3 receptor ligands for the treatment of tobacco dependence. Expert.Opin. Investig.Drugs, 16, 45-57.
85. Leonard, S., Breese, C., Adams, C., Benhammou, K., Gault, J., Stevens, K. et al. (2000). Smoking and schizophrenia: Abnormal nicotinic receptor expression. Eur.J.Pharmacol., 393, 237-242.
86. Lerman, C. (2006). Helping smokers quit through pharmacogenetics. LDI.Issue.Brief., 11, 1-4.
87. Levin, E. D., Bettegowda, C., Weaver, T., & Christopher, N. C. (1998). Nicotine-dizocilpine interactions and working and reference memory performance of rats in the radial-arm maze. Pharmacol.Biochem.Behav., 61, 335-340.
88. Levin, E. D., Christopher, N. C., Briggs, S. J., & Rose, J. E. (1993). Chronic nicotine reverses working memory deficits caused by lesions of the fimbria or medial basalocortical projection. Brain Res.Cogn Brain Res., 1, 137-143.
89. Levin, E. D., Petro, A., & Beatty, A. (2005). Olanzapine interactions with nicotine and mecamylamine in rats: Effects on memory function. Neurotoxicol.Teratol., 27, 459-464.
90. Levin, E. D. & Rezvani, A. H. (2006). Nicotinic-antipsychotic drug interactions and cognitive function. EXS, 98, 185-205.
91. Levin, E. D., Wilson, W., Rose, J. E., & McEvoy, J. (1996). Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology, 15, 429-436.
92. Lin, Y. H., Liu, C. Y., & Hsiao, M. C. (2005). Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin.Neurosci., 59, 613-615.
93. Maldonado, R., Valverde, O., & Berrendero, F. (2006). Involvement of the endocannabinoid system in drug addiction. Trends Neurosci., 29, 225-232.
94. Marchesi, G. F., Santone, G., Cotani, P., Giordano, A., & Chelli, F. (1995). The t herapeutic role of naltrexone in negative symptom schizophrenia. Prog. Neuropsychopharmacol. Biol.Psychiatry, 19, 1239-1249.
95. Martin, L. F., Kem, W. R., & Freedman, R. (2004). Alpha-7 nicotinic receptor agonists: Potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl), 174, 54-64.
96. McCloughen, A. (2003). The association between schizophrenia and cigarette smoking: A review of the literature and implications for mental health nursing practice. Int.J.Ment.Health Nurs., 12, 119-129.
97. McCreadie, R. G. (2003). Diet, smoking and cardiovascular risk in people with schizophrenia: Descriptive study. Br.J.Psychiatry, 183, 534-539.
98. McDaniel, W. W., Spiegel, D. R., & Sahota, A. K. (2006). Topiramate effect in catatonia: A case series. J.Neuropsychiatry Clin.Neurosci., 18, 234-238.
99. McEvoy, J., Freudenreich, O., McGee, M., VanderZwaag, C., Levin, E., & Rose, J. (1995a). Clozapine decreases smoking in patients with chronic schizophrenia. Biol.Psychiatry, 37, 550-552.
100. McEvoy, J. P. & Brown, S. (1999). Smoking in first-episode patients with schizophrenia. Am.J.Psychiatry, 156, 1120-1121.
101. McEvoy, J. P., Freudenreich, O., Levin, E. D., & Rose, J. E. (1995b). Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl), 119, 124-126.
102. McEvoy, J. P., Freudenreich, O., & Wilson, W. H. (1999). Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol.Psychiatry, 46, 125-129.
103. McEvoy, J. P., Schooler, N. R., & Wilson, W. H. (1991). Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacol.Bull., 27, 97-101.
104. Mello, N. K., Lukas, S. E., & Mendelson, J. H. (1985). Buprenorphine effects on cigarette smoking. Psychopharmacology (Berl), 86, 417-425.
105. Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006). Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol. Pharmacol., 70, 801-805.
106. Moller, H. J. (2000). State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J.Biol.Psychiatry, 1, 204-214.
107. Montoya, I. D., Herbeck, D. M., Svikis, D. S., & Pincus, H. A. (2005). Identification and treatment of patients with nicotine problems in routine clinical psychiatry practice. Am.J.Addict., 14, 441-454.
108. Mutschler, N. H., Stephen, B. J., Teoh, S. K., Mendelson, J. H., & Mello, N. K. (2002). An inpatient study of the effects of buprenorphine on cigarette smoking in men concurrently dependent on cocaine and opioids. Nicotine.Tob.Res., 4, 223-228.
109. Nagamoto, H. T., Adler, L. E., Hea, R. A., Griffith, J. M., McRae, K. A., & Freedman, R. (1996). Gating of auditory P50 in schizophrenics: Unique effects of clozapine. Biol.Psychiatry, 40, 181-188.
110. O'Malley, S. S., Cooney, J. L., Krishnan-Sarin, S., Dubin, J. A., McKee, S. A., Cooney, N. L. et al. (2006). A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch.Intern.Med., 166, 667-674.
111. Olincy, A., Johnson, L. L., & Ross, R. G. (2003). Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res., 117, 223-236.
112. Olincy, A., Young, D. A., & Freedman, R. (1997). Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol.Psychiatry, 42, 1-5.
113. Oncken, C., Gonzales, D., Nides, M., Rennard, S., Watsky, E., Billing, C. B. et al. (2006). Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch.Intern.Med., 166, 1571-1577.
114. Oranje, B., Van Oel, C. J., Gispen-De Wied, C. C., Verbaten, M. N., & Kahn, R. S. (2002). Effects of typical and atypical antipsychotics on the prepulse inhibition of the startle reflex in patients with schizophrenia. J.Clin.Psychopharmacol., 22, 359-365.
115. Oyewumi, L. K. (1998). Smoking cessation and clozapine side effects. Can.J.Psychiatry, 43, 748.
116. Perenyi, A., Goswami, U., Frecska, E., Arato, M., & Bela, A. (1992). L-deprenyl in treating negative symptoms of schizophrenia. Psychiatry Res., 42, 189-191.
117. Picciotto, M. R. (2003). Nicotine as a modulator of behavior: Beyond the inverted U. Trends Pharmacol.Sci., 24, 493-499.
118. Picciotto, M. R. & Corrigall, W. A. (2002). Neuronal systems underlying behaviors related to nicotine addiction: Neural circuits and molecular genetics. J.Neurosci., 22, 3338-3341.
119. Procyshyn, R. M., Tse, G., Sin, O., & Flynn, S. (2002). Concomitant clozapine reduces smoking in patients treated with risperidone. Eur.Neuropsychopharmacol., 12, 77-80.
120. Punnoose, S. & Belgamwar, M. R. (2006). Nicotine for schizophrenia. Cochrane.Database. Syst.Rev., CD004838.
121. Reynolds, G. P., Templeman, L. A., & Godlewska, B. R. (2006). Pharmacogenetics of schizophrenia. Expert.Opin.Pharmacother., 7, 1429-1440.
122. Sacco, K. A., Termine, A., Dudas, M. M., Seyal, A. A., Allen, T. M., Vessicchio, J. C. et al. (2006). Neuropsychological deficits in nonsmokers with schizophrenia: Effects of a nicotinic antagonist. Schizophr.Res., 85, 213-221.
123. Schmauss, C., Yassouridis, A., & Emrich, H. M. (1987). Antipsychotic effect of buprenorphine in schizophrenia. Am.J.Psychiatry, 144, 1340-1342.
124. Schnoll, R. A. & Lerman, C. (2006). Current and emerging pharmacotherapies for treating tobacco dependence. Expert.Opin.Emerg.Drugs, 11, 429-444.
125. Seppala, N. H., Leinonen, E. V., Lehtonen, M. L., & Kivisto, K. T. (1999). Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol.Toxicol., 85, 244-246.
126. Sharma, T., Reed, C., Aasen, I., & Kumari, V. (2006). Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation. Schizophr.Res., 85, 73-83.
127. Silver, H. (2004). Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert.Opin. Pharmacother., 5, 2053-2058.
128. Skogh, E., Bengtsson, F., & Nordin, C. (1999). Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Ther.Drug Monit., 21, 580-582.
129. Slemmer, J. E., Martin, B. R., & Damaj, M. I. (2000). Bupropion is a nicotinic antagonist. J.Pharmacol.Exp.Ther., 295, 321-327.
130. Smith, R. C., Singh, A., Infante, M., Khandat, A., & Kloos, A. (2002). Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology, 27, 479-497.
131. Smith, R. C., Warner-Cohen, J., Matute, M., Butler, E., Kelly, E., Vaidhyanathaswamy, S. et al. (2006). Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology, 31, 637-643.
132. Sofuoglu, M., Poling, J., Mouratidis, M., & Kosten, T. (2006). Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl), 184, 645-651.
133. Sokoloff, P., Diaz, J., Le Foll, B., Guillin, O., Leriche, L., Bezard, E. et al. (2006). The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS.Neurol.Disord.Drug Targets., 5, 25-43.
134. Sumiyoshi, T., Kido, H., Sakamoto, H., Urasaki, K., Suzuki, K., Yamaguchi, N. et al. (1994). In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol. Pharmacol.Biochem.Behav., 47, 553-557.
135. Upadhyaya, H. P., Brady, K. T., & Wang, W. (2004). Bupropion SR in adolescents with comorbid ADHD and nicotine dependence: a pilot study. J.Am.Acad.Child Adolesc.Psychiatry, 43, 199-205.
136. Warner, C. & Shoaib, M. (2005). How does bupropion work as a smoking cessation aid? Addict.Biol., 10, 219-231.
137. Weiner, E., Ball, M. P., Summerfelt, A., Gold, J., & Buchanan, R. W. (2001). Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am.J.Psychiatry, 158, 635-637.
138. Wetzel, H., Anghelescu, I., Szegedi, A., Wiesner, J., Weigmann, H., Harter, S. et al. (1998). Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study. J.Clin.Psychopharmacol., 18, 2-9.
139. Wilens, T. E., Haight, B. R., Horrigan, J. P., Hudziak, J. J., Rosenthal, N. E., Connor, D. F. et al. (2005). Bupropion XL in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study. Biol.Psychiatry, 57, 793-801.
140. Williams, J. M. & Ziedonis, D. (2004). Addressing tobacco among individuals with a mental illness or an addiction. Addict.Behav., 29, 1067-1083.
141. Williams, J. M., Ziedonis, D. M., Abanyie, F., Steinberg, M. L., Foulds, J., & Benowitz, N. L. (2005). Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophr. Res.
142. Williams, J. M., Ziedonis, D. M., & Foulds, J. (2004). A case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia. Psychiatr.Serv., 55, 1064-1066.
143. Ziedonis, D. & Brady, K. (1997). Dual diagnosis in primary care. Detecting and treating both the addiction and mental illness. Med Clin North Am., 81, 1017-1036.
144. Ziedonis, D. M. (2004). Integrated treatment of co-occurring mental illness and addiction: Clinical intervention, program, and system perspectives. CNS.Spectr., 9, 892-904, 925.
145. Ziedonis, D. M. & George, T. P. (1997). Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr.Bull., 23, 247-254.
146. Ziedonis, D. M., Smelson, D., Rosenthal, R. N., Batki, S. L., Green, A. I., Henry, R. J. et al. (2005). Improving the care of individuals with schizophrenia and substance use disorders: Consensus recommendations. J.Psychiatr Pract., 11, 315-339.